Application of Fragment-Based Drug Discovery against DNA GyraseB

被引：14

作者：

Chen, Guo-Ying ^{[1
]}

Ng, Fui Mee ^{[1
]}

Tan, Yih Wan ^{[1
]}

Poulsen, Anders ^{[1
]}

Seetoh, Weiguang ^{[1
]}

Lin, Grace ^{[1
]}

Kang, CongBao ^{[1
]}

Then, Siew Wen ^{[1
]}

Ahmad, Nur Huda ^{[1
]}

Wong, Ying Lei ^{[1
]}

Ng, Hui Qi ^{[1
]}

Chia, C. S. Brian ^{[1
]}

Lau, Qiu Ying ^{[1
]}

Hill, Jeffrey ^{[1
]}

Hung, Alvin W. ^{[1
]}

Keller, Thomas H. ^{[1
]}

机构：

[1] ASTAR, Ctr Expt Therapeut, Singapore 138667, Singapore

来源：

CHEMPLUSCHEM | 2015年 / 80卷 / 08期

关键词：

antibiotics; drug design; drug discovery; inhibitors; ligand effects; MYCOBACTERIUM-TUBERCULOSIS; ANTIBACTERIAL AGENTS; TOPOISOMERASE-IV; B PROTEIN; INHIBITORS; OPTIMIZATION; POTENT; HIT; RESISTANCE; DESIGN;

D O I：

10.1002/cplu.201500197

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Bacterial resistance to antibiotics remains a serious threat to global health. The gyraseB enzyme is a well-validated target for developing antibacterial drugs. Despite being an attractive target for antibiotic development, there are currently no gyraseB inhibitory drugs on the market. A fragment screen using 1,800compounds identified 14fragments that bind to Escherichia coli (E.coli) gyraseB. The detailed characterization of binding is described for all 14fragments. With the aid of X-ray crystallography, modifications on a low-affinity fragment (K-D=253M, IC50=634M) has led to the development of a new class of potent phenyl aminopyrazole inhibitors against E.coli gyraseB (IC50=160nM). The study presented here combines the use of a set of biophysical techniques including differential scanning fluorimetry, nuclear magnetic resonance, isothermal titration calorimetry, and X-ray crystallography to methodically identify, quantify, and optimize fragments into new chemical leads.

引用

页码：1250 / 1254

页数：5

共 50 条

[31] Fragment-based drug discovery takes a virtual turn
Maurizio Pellecchia
Nature Chemical Biology, 2009, 5 : 274 - 275
[32] Fragment-based drug discovery using the SHAPES method
Lepre, Christopher
EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (12) : 1555 - 1566
[33] Fragment-based drug discovery: opportunities for organic synthesis
St Denis, Jeffrey D.
Hall, Richard J.
Murray, Christopher W.
Heightman, Tom D.
Rees, David C.
RSC MEDICINAL CHEMISTRY, 2021, 12 (03): : 321 - 329
[34] Applied Biophysical Methods in Fragment-Based Drug Discovery
Coyle, Joe
Walser, Reto
SLAS DISCOVERY, 2020, 25 (05) : 471 - 490
[35] Fragment-based drug discovery using NMR spectroscopy
Mary J. Harner
Andreas O. Frank
Stephen W. Fesik
Journal of Biomolecular NMR, 2013, 56 : 65 - 75
[36] Covalent fragment-based drug discovery for target tractability
McCarthy, William J.
van der Zouwen, Antonie J.
Bush, Jacob T.
Rittinger, Katrin
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2024, 86
[37] USING COMPUTATIONAL TECHNIQUES IN FRAGMENT-BASED DRUG DISCOVERY
DesJarlais, Renee L.
FRAGMENT-BASED DRUG DESIGN: TOOLS, PRACTICAL APPROACHES, AND EXAMPLES, 2011, 493 : 137 - 155
[38] Fragment-based drug discovery: From crystal to clinic
Howard, Steven
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 559 - 559
[39] Fragment-based drug discovery using NMR spectroscopy
Harner, Mary J.
Frank, Andreas O.
Fesik, Stephen W.
JOURNAL OF BIOMOLECULAR NMR, 2013, 56 (02) : 65 - 75
[40] Native Mass Spectrometry in Fragment-Based Drug Discovery
Pedro, Liliana
Quinn, Ronald J.
MOLECULES, 2016, 21 (08)

← 1 2 3 4 5 →